Journal
CHEMICO-BIOLOGICAL INTERACTIONS
Volume 171, Issue 2, Pages 190-194Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.cbi.2007.03.008
Keywords
nanomedicine; nanobiotechnology; drug delivery; quantum dots; PACAP; galanin; DSPE-PEG2000; phosphatidylcholine
Funding
- NCRR NIH HHS [C06RR15482, C06 RR015482] Funding Source: Medline
- NHLBI NIH HHS [R01 HL72323, R01 HL072323] Funding Source: Medline
- NIA NIH HHS [R01 AG024026-01, R01 AG024026] Funding Source: Medline
Ask authors/readers for more resources
The purpose of this study was to determine whether biocompatible and biodegradable vasoactive intestinal peptide-grafted sterically stabilized phospholipid mixed nanomicelles (VIP-SSMM; size, similar to 15 nm), a novel nanosized actively targeted drug delivery platform for breast cancer, accumulate in human MCF-7 breast cancer cells. Using hydrophobic CdSe/ZnS quantum dots (QD), we found that QD-loaded VIP-SSMM accumulated significantly faster and in greater quantity in MCF-7 cells than did QD-loaded SSMM alone (p < 0.05). This process was mediated, in part, by VIP receptors because excess human VIP, but not PACAP(6-38) or galanin, significantly attenuated this response (p < 0.05). Taken together, these data indicate that VIP-SSMM are actively targeted to human breast cancer cells through VIP receptors. We suggest that VIP-SSMM could be used as an actively targeted nanosized drug delivery platform for breast cancer cells over-expressing VIP receptors. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
